Introduction: We aim to review the outcomes of micropapillary urothelial carcinoma (MPUC) of the bladder from a single institution. The hypothesis is that non-muscle-invasive (NMI) MPUC may have a heterogeneous prognosis, and detailed pathological analysis may identify patients that could be managed without immediate cystectomy. Patients and Methods: This is a retrospective analysis of patients presenting with MPUC in a primary transurethral resection specimen (n = 40). The pattern of micropapillary (MP) differentiation [surface/non-invasive (sMP) or invasive (iMP)], extent of MP differentiation and lymphovascular invasion (LVI) were correlated with overall survival (OS), recurrence-free survival and upstaging at re-resection. Results: Sixteen of 40 patients died after a median follow-up of 37 months. Tumour stage was strongly predictive of OS (p < 0.0001). LVI was associated with increased mortality (hazard ratio 12.4, 95% CI: 3.5-44.5, p = 0.0001), higher pathological stage (p = 0.001), lymph node involvement (p = 0.001) and iMP differentiation (p = 0.006). In NMI patients not undergoing cystectomy (n = 17), NMI-sMP compared with NMI-iMP differentiation was associated with an improved OS when compared with iMP (63 vs. 47 months, p = 0.05). Conclusions: MPUC is an aggressive variant of urothelial carcinoma (UC). Similar to conventional UC, LVI associated with MPUC is an adverse prognostic indicator. iMP is a morphological marker for LVI. Histopathological reports should distinguish between sMP and iMP differentiation.

Keywords:
Micropapillary, Urothelial carcinoma variants, Bladder cancer, Lymphovascular invasion
1.
Nassar H: Carcinomas with micropapillary morphology - clinical significance and current concepts. Adv Anat Pathol 2004;11:297-303.
2.
Amin MB, Ro JY, Elsharkawy T, Lee KM, Troncoso P, Silva EG, Ordonez NG, Ayala AG: Micropapillary variant of transitional-cell carcinoma of the urinary-bladder - histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994;18:1224-1232.
3.
Johansson SL, Borghede G, Holmang S: Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 1999;161:1798-1802.
4.
Kamat AM, Dinney CPN, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL: Micropapillary bladder cancer - a review of the University of Texas MD Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007;110:62-67.
5.
McQuitty E, Ro JY, Truong LD, Shen SS, Zhai Q, Ayala AG: Lymphovascular invasion in micropapillary urothelial carcinoma a study of 22 cases. Arch Pathol Lab Med 2012;136:635-639.
6.
Hansel DE, Amin MB, Comperat E, Cote RJ, Knuchel R, Montironi R, Reuter VE, Soloway MS, Umar SA, Van der Kwast TH: A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 2013;63:321-332.
7.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Comperat E, Sylvester RJ, Kaasinen E, Boehle A, Palou Redorta J, Roupret M: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-653.
8.
Gaya JM, Palou J, Algaba F, Arce J, Rodriguez-Faba O, Villavicencio H: The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 2010;17:5370-5376.
9.
Amin A, Epstein JI: Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. Hum Pathol 2012;43:2124-2128.
10.
Comperat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaid I, Cussenot O, Samaratunga H: Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 2010;42:650-654.
11.
Maranchie JK, Bouyounes BT, Zhang PL, O'Donnell MA, Summerhayes IC, DeWolf WC: Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 2000;163:748-751.
12.
Samaratunga H, Khoo K: Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology 2004;45:55-64.
13.
Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G, Appelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON: Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors 2011;3:e22-e22.
14.
Cheng L, Montironi R, Davidson DD, Lopez-Beltran A: Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009;22:S70-S95.
15.
Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T, Lee CT, Shah RB: Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007;70:69-74.
16.
Amin MB: Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 2009;22:S96-S118.
17.
Fairey AS, Daneshmand S, Wang LN, Schuckman A, Lieskovsky G, Djaladat H, Cai J, Miranda G, Skinner EC: Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol 2014;32:110-116.
18.
Wang JK, Boorjian SA, Cheville JC, Kim SP, Tarrell RF, Thapa P, Frank I: Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol 2012;30:801-806.
19.
Spaliviero M, Dalbagni G, Bochner BH, Poon BY, Huang H, Al-Ahmadie HA, Donahue TF, Taylor JM, Meeks JJ, Sjoberg DD, Donat SM, Reuter VE, Herr HW: Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. J Urol 2014;192:702-707.
20.
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM: Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol 2014;32:826-832.
21.
Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH: Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol;182:2625-2631.
22.
Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, Iczkowski KA, Lopez-Beltran A, Oliva E, Paner GP, Reuter VE, Ro JY, Shah, RB, Shen SS, Tamboli P, McKenney JK: Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 2010;34:1367-1376.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.